Production (Stage)
The Oncology Institute, Inc.
TOI
$3.02
$0.031.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.29% | 16.88% | 21.78% | 22.88% | 24.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.29% | 16.88% | 21.78% | 22.88% | 24.25% |
| Cost of Revenue | 5.39% | 19.92% | 29.49% | 31.40% | 33.18% |
| Gross Profit | 44.11% | 1.79% | -10.09% | -13.83% | -15.11% |
| SG&A Expenses | -10.81% | -11.86% | -5.39% | -2.79% | -1.31% |
| Depreciation & Amortization | 19.81% | 8.24% | -7.36% | 14.22% | 17.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.49% | 10.88% | 18.59% | 20.86% | 22.18% |
| Operating Income | 44.85% | 22.54% | 0.22% | -9.95% | -12.33% |
| Income Before Tax | 1.53% | 30.87% | 6.78% | 7.85% | 33.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.53% | 29.71% | 7.50% | 8.39% | 33.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.53% | 29.71% | 7.50% | 8.39% | 33.70% |
| EBIT | 44.85% | 22.54% | 0.22% | -9.95% | -12.33% |
| EBITDA | 50.69% | 26.05% | -0.77% | -9.53% | -11.89% |
| EPS Basic | 5.19% | 31.23% | 9.84% | 9.06% | 19.67% |
| Normalized Basic EPS | 22.49% | 35.34% | 6.15% | 7.19% | -41.26% |
| EPS Diluted | 5.19% | 30.77% | 7.31% | 10.53% | 19.67% |
| Normalized Diluted EPS | 22.49% | 35.34% | 6.15% | 7.19% | -41.26% |
| Average Basic Shares Outstanding | 3.86% | 2.98% | 2.80% | 0.85% | 1.07% |
| Average Diluted Shares Outstanding | 3.86% | 2.98% | 2.80% | 0.85% | 1.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |